Overview

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Status:
Completed
Trial end date:
2018-05-08
Target enrollment:
Participant gender:
Summary
This non-interventional prospective study is a post-authorization safety study (PASS) of vernakalant conducted to collect information about normal conditions of use and appropriate dosing, and to quantify possible medically significant risks associated with the use of vernakalant in real-world clinical practice.
Details
Lead Sponsor:
Cardiome Pharma
Correvio International Sarl